Pharma Cos. Owe $30M For Acquired Drug's Gains, Suit Says
Former shareholders of Rempex Pharmaceuticals Inc. are owed a $30 million milestone payment from two subsequent owners of a Rempex infection treatment due to the drug's regulatory approval, an investment adviser...To view the full article, register now.
Already a subscriber? Click here to view full article